Since then, Theresa has been undetectable for over a year, and she continues treatment with Keytruda, with little to no side effects. Her family remains hopeful and grateful that everything is going well for Theresa and they pray for her continued strength.

Merck has now added a real doctor to its TV ad for Keytruda (pembrolizumab), the cancer immunotherapeutic. Two new ads – one featuring Dr. Goetz Kloecker, a practicing oncologist, alone and one featuring Dr.

Half (50%) of the patients who received Keytruda every 3 weeks were alive at 4.1 months, compared to 2.8 months for patients receiving Yervoy. Keytruda was shown to reduce the risk of dying by 31% compared to Yervoy.

The average overall survival duration among Keytruda treated patients is now 26.3 months compared to 14.2 months for those treated with chemotherapy. The 36-month overall survival is 43.7% for Keytruda compared to 24.9% for chemotherapy.

The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $11,115.04. The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $22,230.08. * Most people will not pay the list price, although it may have an impact on your out-of-pocket costs.

Patients receiving Keytruda lived for 10.3 months (median overall survival) compared to 7.4 months with chemotherapy.

KEYTRUDA plus carboplatin-paclitaxel or nab-paclitaxel reduced the risk of death by 29% (HR=0.71 [95% CI, 0.59-0.85]) versus chemotherapy alone. The median OS was 17.2 months for the KEYTRUDA plus chemotherapy group versus 11.6 months for the chemotherapy group.

Immunotherapy Benefit for Advanced Lung Cancer Continues Beyond 2 Years. Limiting immunotherapy to 2 years doesn't decrease survival odds, but may reduce bothersome side effects and improve quality of life.

Researchers investigated the 5-year outcome of an immunotherapy drug on early-stage lung cancer. 80% of those who took the immunotherapy drug survived after 5 years, whereas survival rates from standard treatments are 36–68%.

The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $11,115.04. The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $22,230.08. * Most people will not pay the list price, although it may have an impact on your out-of-pocket costs.

The average price of Immunotherapy with Keytruda (Pembolizumab) in Germany is $9377, the minimum price is $7050, and the maximum price is $13038.

The optimal duration of ICI use, however, is not known. Patients in key pivotal studies informing the use of first-line immunotherapy use were treated with ICI therapy for up to 2 years (maximum of 35 cycles every 3 weeks); in clinical practice, however, many patients continue therapy beyond 2 years.